ArticleClinical interventions in aging2026
Efficacy of First-Line EGFR-TKI Treatment in Octogenarians with Lung Adenocarcinoma and Common EGFR Mutations.
Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective cohort study compared the efficacy and tolerability of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) between octogenarians (aged ≥80 years) and non-octogenarians with advanced EGFR-mutated lung adenocarcinoma. Methods: We retrospectively analyzed 151 patients with advanced lung adenocarcinoma harboring common EGFR exon 19 deletions or exon 21 L858R mutations who received first-line EGFR-TKI therapy. Patient characteristics, treatment outcomes, and adverse events were evaluated. Results: Progression-free survival (PFS) did not differ significantly between octogenarians and non-octogenarians. Overall survival (OS) was shorter in octogenarians, which may be partly explained by lower rates of subsequent therapy and age-related clinical factors. No significant differences in treatment-related toxicities were observed between the two groups. Conclusion: This study provides clinically relevant real-world evidence supporting the feasibility of first-line EGFR-TKI therapy in octogenarians with EGFR-mutated lung adenocarcinoma. Chronological age alone should not preclude carefully selected very elderly patients from receiving EGFR-TKI treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.